QUEBEC CITY & SAINT PAUL, Minn.--(BUSINESS WIRE)--Regulatory News: Medicago Inc. (TSX: MDG; OTCQX: MDCGF), (“Medicago”) a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus Like Particles (“VLP”s), and Cellectis plant sciences, a US-based subsidiary of Cellectis Group (Alternext: ALCLS), (“Cellectis”), the specialist in genome engineering, today announced the successful completion of the first step in their research collaboration to improve therapeutic proteins produced in tobacco plants.
